Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04891614
Other study ID # CLP001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 29, 2020
Est. completion date June 1, 2022

Study information

Verified date April 2022
Source GrayMatters Health Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Prospective, Single-Arm, Open-Label Pilot Trial, to Assess Safety and Effectiveness of Process-Instructed Self neuro-Modulation ("Prism"), as an Adjunct to Standard of Care, in Subjects with Post-Traumatic Stress Disorder (PTSD)


Description:

Prism is a software device intended for neurofeedback (NF) training (i.e. operant condition based on EEG signals, also known as EEG-biofeedback), to be used in combination with a standard computer and supported EEG hardware. For purposes of this training, information for feedback is derived and processed from several EEG channels. Prism provides visual and/or auditory signals that correspond to the patient's computed EEG signal, which serves as a surrogate indicator of achieving a state of reduced amygdala activity. The study is a Prospective, Single-Arm, Open-Label Pilot Trial, to Assess Safety and Effectiveness of Process-Instructed Self neuro-Modulation ("Prism"), as an Adjunct to Standard of Care, in Subjects with Post-Traumatic Stress Disorder (PTSD). The study population will include subjects diagnosed with Post-Traumatic Stress Disorder (PTSD) from 1 year to 20 years after index trauma. The total expected enrollment is up to 100 subjects in one or more sites. The study's primary objective is to assess the safety and effectiveness of fifteen (15) EEG-NF training sessions using the Prism software in reducing PTSD-related symptoms.


Recruitment information / eligibility

Status Completed
Enrollment 87
Est. completion date June 1, 2022
Est. primary completion date May 31, 2022
Accepts healthy volunteers No
Gender All
Age group 22 Years to 65 Years
Eligibility Inclusion Criteria: 1. Ages 22 to 65 2. Any gender 3. Diagnosis of PTSD, established according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) 4. 1 to 20 years since index trauma 5. Ability to give signed, informed consent 6. Normal or corrected-to-normal vision 7. Normal or corrected to normal hearing 8. Subject is able to adhere to the study schedule Exclusion Criteria: 1. Have completed two or more full courses of trauma-focused therapy in the past (i.e., EMDR, Prolong Exposure Therapy, etc.), eligibility will be deemed upon the clinical judgment of the investigator. 2. Lifetime diagnosis for schizophrenia, schizoaffective disorder, schizophreniform disorder, Bipolar I disorder, or delusional disorder 3. Any mood disorder and anxiety disorder according to DSM-5 (in addition to those described in Exclusion 2) that is the primary focus of treatment in the last 6 months prior to screening, as per the clinical judgment of the investigator 4. Lifetime diagnosis of autism, mental retardation at the discretion of the investigator. 5. Diagnosis of moderate or severe substance use disorder within the last 3 months of screening visit (as defined in DSM-5-substance use disorder) or at screening visit 6. Any prescribed Benzodiazepine which cannot be ceased for the duration of the study (with a washout period of at least 2 weeks prior to the first Prism training session) or which cannot be replaced with short-acting benzodiazepines that are taken only for sleeping during the night 7. Any psychotropic medication other than a stable dose of selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs) 8. Any change in or initiation of- SSRIs or SNRIs antidepressants within the past 4 weeks. At the time of recruitment, subjects must have no intention of changing their medication or psychotherapy during the study duration 9. Any suicidal behavior in the past 1 year (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior) prior to screening and during the screening period 10. Recent initiation (within the past 3 months) of cognitive-behavioral therapy or any evidence-based PTSD psychotherapy (Cognitive Processing Therapy [CPT], Prolonged Exposure [PE], Eye Movement Desensitization and Reprocessing [EMDR]); continuation of established maintenance supportive therapy will be permitted 11. Any history of brain surgery, of penetrating, neurovascular, infectious, or other major brain injury, of epilepsy, or of other major neurological abnormality (including a history of traumatic brain injury [TBI] with loss of consciousness for more than 24 hours or posttraumatic amnesia for more than 7 days) 12. Any unstable medical condition, as per the clinical judgement of the investigator 13. In process of establishing/changing governmental/institutional compensation payments for PTSD symptoms 14. Enrollment in another clinical study at screening or within 2 months prior to screening, or intended enrollment within the duration of this study 15. Women who are pregnant, nursing, or who plan to become pregnant while in the trial

Study Design


Related Conditions & MeSH terms


Intervention

Device:
PRISM
Subjects will complete 15 neurofeedback training sessions delivered twice per week, on non-consecutive days, over 8 consecutive weeks.

Locations

Country Name City State
Israel Barzilai Medical Center Ashkelon
Israel Rambam Health Care Campus Haifa
Israel Mental Health Center in Be'er Ya'akov Ness Ziona
Israel Sheba Medical Center Ramat Gan
United States NYU Langone Health New York New York

Sponsors (1)

Lead Sponsor Collaborator
GrayMatters Health Ltd.

Countries where clinical trial is conducted

United States,  Israel, 

Outcome

Type Measure Description Time frame Safety issue
Other Abbreviated PCL (APCL) To assess the change in the score of the abbreviated PCL scale (APCL, assessed weekly during the EFP-NF training period) through study completion, an average of 8 weeks
Other learning success of the EFP-based neurofeedback To quantify the learning success of the EFP-based neurofeedback (namely: learning volitional down-regulation of the Amyg-EFP signal, over time, during the EFP-NF training period) through study completion, an average of 8 weeks
Other Patient satisfaction survey To quantify patient satisfaction from the EFP-NF training using survey through study completion, an average of 5 month
Other Remission rate To assess the Remission rate at post training visit (8-9 weeks) and at the 3 months follow-up visit Baseline visit (Week 1), Post-Intervention Visit (Week 9) and 3 month Follow-up visit
Primary Clinician Administered PTSD Scale (CAPS - 5) The primary objective of this study is to assess the proportion of subjects who demonstrate clinically meaningful improvement in the Clinician Administered PTSD Scale (CAPS - 5) score from Baseline to the 3 months follow-up visit. Clinically meaningful improvement is defined here as a 6-point reduction or more in the CAPS-5 score. Baseline visit (Week 1) and 3 month Follow-up visit
Secondary PCL-5 response rate To assess the proportion of subjects who demonstrate clinically meaningful improvement in the PTSD Checklist for DSM-5 (PCL-5). Clinically meaningful improvement is defined here as a 10-point reduction or more in the PCL-5 score Baseline visit (Week 1), Post-Intervention Visit (Week 9) and 3 month Follow-up visit
Secondary ERQ score Change from baseline to Month 3 visit in ERQ score Baseline visit (Week 1), Post-Intervention Visit (Week 9) and 3 month Follow-up visit
Secondary PHQ-9 score Change from baseline to Month 3 visit in PHQ-9 score Baseline visit (Week 1), Post-Intervention Visit (Week 9) and 3 month Follow-up visit
Secondary Clinical Global Impression (CGI) Change from baseline to Month 3 visit in CGI score Baseline visit (Week 1), Post-Intervention Visit (Week 9) and 3 month Follow-up visit
See also
  Status Clinical Trial Phase
Terminated NCT05189977 - A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline Phase 1
Completed NCT01806168 - rTMS in the Treatment of PTSD N/A
Not yet recruiting NCT06194851 - Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD Phase 2
Completed NCT02187224 - Progesterone Effect on Individuals Diagnoses With AD and PTSD. Phase 2/Phase 3
Completed NCT02549508 - Comparison Study Using APAP With and Without SensAwake in Patients With OSA and PTSD N/A
Not yet recruiting NCT01940549 - Transcranial Direct Current Stimulation (tDCS) Enhancement of Trauma-focused Therapy for Posttraumatic Stress Disorder N/A
Completed NCT02012738 - Treatment of Trauma and Violence in the Townships of South Africa N/A
Not yet recruiting NCT06419959 - NightWare and Cardiovascular Health in Veterans With PTSD N/A
Terminated NCT03209882 - Transcranial Infrared Laser Stimulation (TILS) of Prefrontal Cognition in Post-traumatic Stress Disorder (PTSD) N/A
Recruiting NCT05407337 - The Effect of Narrative Exposure Therapy Intervention on Post-traumatic Stress Dissorder and Personal Recovery in Refugees and Asylum Seekers of Sindiane Programme N/A
Completed NCT02030522 - Prospective Cohort Study of Accelerated Resolution Therapy (ART) for Treatment of Military Psychological Trauma N/A
Completed NCT01729325 - Prevention of Post-Traumatic Stress Disorder in Soldiers Phase 2
Completed NCT02053532 - Functional Brain Imaging in PTSD N/A
Not yet recruiting NCT02598024 - Treating Earthquake in Nepal Trauma (TENT) Trial 2016 N/A
Terminated NCT02237703 - Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD) N/A
Withdrawn NCT02356861 - LED Light Therapy to Improve Cognitive & Psychosocial Function in TBI-PTSD Veterans N/A
Not yet recruiting NCT05974631 - Evaluating Treatments for Suicidal Veterans With PTSD N/A
Not yet recruiting NCT06288594 - TraumaRelief App: A Pilot RCT Assessing Feasibility and Acceptability N/A
Completed NCT01847469 - Zonisamide in Addition to E-CPT-C for Veterans With PTSD and Comorbid Alcohol Dependence Phase 2
Completed NCT01691092 - PET Imaging of mGLuR5 With Drug Challenge N/A